News
With the revolutionary gene therapy Luxturna being reviewed by Canada’s health agencies this summer, the year 2020 marks a crucial moment in the history of inherited retinal diseases (IRDs), which until now…
Read More about Luxturna Update: Vision Loss Community TellS Policymakers What it’s Like to Live with an IRD
Introduction My name is Marlene Cust. I am a senior citizen, and legally blind due to retinitis pigmentosa (RP) and age-related macular degeneration (AMD). In my writing, I want to acknowledge both…
Read More about The Way I See It Blog Series: In Praise of a Dog
It’s difficult to imagine life without your digital screens, especially at a time when we continue to practice physical distancing to stop the spread of COVID-19. However, with an estimated 1.5 million…
Read More about ARE YOU UP FOR THE CHALLENGE?
Age-related macular degeneration (AMD) is the leading cause of vision loss in people over the age of 50, affecting approximately 1.4 million Canadians. There are two kinds of AMD: dry AMD which…
Read More about Improving AMD Treatments by Studying Cell Movement
Valproic acid (VA), belongs to a family of drugs called HDAC inhibitors (HDACi) and has been tested as a potential treatment for retinitis pigmentosa (RP) with mixed results. In some clinical trials,…
Read More about BIOLOGICAL MECHANISMS DRIVING HDAC INHIBITOR TREATMENT EFFECTS IN RP
Introduction My name is Marlene Cust. I am a senior citizen, and legally blind due to retinitis pigmentosa (RP) and age-related macular degeneration (AMD). In my writing, I want to acknowledge both…
Read More about The Way I See It Blog Series: Walking in BeautyJoin the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.
